P1A tumor-associated antigen (P1A)

P1A is a well-characterized tumor-associated antigen, specifically a cancer-testis antigen, originally identified in the mouse P815 mastocytoma model (Van den Eynde et al., 1991, Science). It is encoded by the Trap1 gene and is expressed in various tumors but restricted to the testis and placenta in normal tissues, making it an ideal target for immunotherapy due to the immune-privileged status of these organs (Lethe et al., 1992, Eur J Immunol). The target complex consists of a specific P1A-derived peptide (typically LPYLGWLVF) presented by MHC class I molecules (H-2Ld in mice) on the surface of tumor cells or antigen-presenting cells. Therapeutic strategies targeting this complex include T-cell receptor (TCR) engineered T-cells, cancer vaccines, and TCR-like antibodies designed to recognize the peptide-MHC interface (Rosato et al., 2001, Cancer Research). These interventions aim to trigger a robust cytotoxic T-lymphocyte response to eliminate tumor cells while sparing most healthy tissues.

Other names

Tumor antigen P1ATrap1P815 tumor antigenP1A peptide-MHC complexAntigen P1A

Induction of T-cell mediated cytotoxicity against cells presenting the P1A peptide in the context of MHC class I molecules.